Dr Kuno van der Post
OmniComm Systems, Inc.
Fort Lauderdale, FL, March 27, 2013 – OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced its results of operations for the year ended December 31, 2012.
Revenue for the year ended December 31, 2012 totaled $15.6M, a $2.0M increase over the previous year’s results. “Our record revenue for 2012 is the direct result of our expanded sales and marketing team coupled with our innovative and award winning technology,” remarked Cornelis Wit, CEO. “The marketplace is hearing our message; our products, including TrialMaster, TrialOne and eClinical Suite, continue to differentiate themselves from the competition. New features like automated STDM exporting and Risk-Based Monitoring have bolstered our Electronic Data Capture (EDC) sales in 2012 and I am looking forward to an even better 2013.”
The Company reported EBITDA of $1.2M for the year ended December 31, 2012, a 234% improvement over the prior year’s results. “I am very pleased with the 2012 results. 2012 was the best year in the Company’s history, commented Tom Vickers, CFO. “Our results speak for themselves; the 234% improvement in EBITDA with a 14% improvement in Revenue shows the leverage of our business model. As we continue to grow revenue, we will continue to drive a significant percentage of that revenue to the bottom line. I would like to thank the entire OmniComm team for a great 2012.”
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.